Li Lina, Jin Ting, Hu Liang, Ding Jin
College of Medicine, Jinhua University of Vocational Technology, Jinhua, Zhejiang, China.
Department of Gastroenterology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang, China.
Front Oncol. 2024 Jul 26;14:1402350. doi: 10.3389/fonc.2024.1402350. eCollection 2024.
Bladder cancer is one of the leading causes of mortality globally. The development of bladder cancer is closely associated with alternative splicing, which regulates human gene expression and enhances the diversity of functional proteins. Alternative splicing is a distinctive feature of bladder cancer, and as such, it may hold promise as a therapeutic target. This review aims to comprehensively discuss the current knowledge of alternative splicing in the context of bladder cancer. We review the process of alternative splicing and its regulation in bladder cancer. Moreover, we emphasize the significance of abnormal alternative splicing and splicing factor irregularities during bladder cancer progression. Finally, we explore the impact of alternative splicing on bladder cancer drug resistance and the potential of alternative splicing as a therapeutic target.
膀胱癌是全球主要的致死原因之一。膀胱癌的发展与可变剪接密切相关，可变剪接调节人类基因表达并增加功能蛋白的多样性。可变剪接是膀胱癌的一个显著特征，因此，它有望成为一个治疗靶点。本综述旨在全面讨论膀胱癌背景下可变剪接的现有知识。我们回顾了可变剪接的过程及其在膀胱癌中的调控。此外，我们强调了异常可变剪接和剪接因子异常在膀胱癌进展过程中的重要性。最后，我们探讨了可变剪接对膀胱癌耐药性的影响以及可变剪接作为治疗靶点的潜力。
